Elite Daily, a widely read US based publication targeted at generation Y, reported that VivaGel kills up to 99% of HIV and Herpes following the announce TGA approval of VivaGel coated condoms in Australia. 

The ABC reported that while condoms are the best method of sexual protection available, they are currently not 100% effective in preventing either pregnancy or sexually transmitted infections and so anything you can do to reduce the number of virus particles by inactivating them with a substance like VivaGel would reduce that overall viral load.

Following the announcement that Starpharma received TGA approval for VivaGel coated condoms in Australia, the AFR reported on the significance of the deal for Australian innovation. 

Starpharma today released its Appendix 4C – Quarterly Cashflow report for the period ended 30 June 2014.

Starpharma today announced achievement of a major milestone with the receipt of Conformity Assessment Certification for the VivaGel^® condom by the Australian Therapeutic Goods Administration (TGA). This TGA certification is similar to CE certification of devices (CE Mark) in Europe.

Starpharma today announced that the US Food and Drug Administration (FDA) has granted Special Protocol Assessment (SPA) agreement on the design and planned analyses of the phase 3 clinical studies of the VivaGel® bacterial vaginosis (BV) product for the prevention of recurrent BV.

Starpharma today confirmed Mr Peter Bartels AO will retire as Chairman as part of a planned succession. As announced in November 2013, Mr Rob Thomas AM will succeed Mr Bartels as Chairman, effective today.

In this issue:

› VivaGel^® BV prevention of recurrence: start of phase 3 trials close

› R&D tax incentive cash received

› DEP™ docetaxel trial progressing well

› VivaGel^®-coated condom: preparing for launch

› VivaGel^® BV symptomatic relief product: commercial and regulatory progress

› Strong results for dendrimer enhanced agrochemicals

Download: Shareholder Update: June 2014 ( pdf file, 2MB)

Starpharma today provided an update on the progress of its clinical trial programs, which include the Phase 1 DEP™ docetaxel trial and the Phase 3 pivotal trials of VivaGel^® for prevention of recurrent bacterial vaginosis (BV).

 Highlights:

 Phase 1 DEP™ docetaxel trial:

- Ethics approval at 3 sites in Australia

- Enrolling patients; a number having received multiple cycles of therapy

- No evidence of neutropenia

 Phase 3 VivaGel^® for prevention of recurrent BV:

- Agreement with EMA and FDA on study design

- First ethics approval obtained

- Quintiles CRO engaged

- Nearing commencement

Starpharma today released its Appendix 4C – Quarterly Cashflow report for the period ended 31 March 2014.

The cash balance at 31 March 2014 was $27.8 million. This strong cash position was assisted by the receipt of $4.7 million of R&D tax incentive relating to FY13 expenditures.